GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Conceptus, Inc. (CPTS) [hlAlert]

Rating:
Hold CPTS

Conceptus, Inc. (CPTS) rated Hold with price target $18 by Wunderlich

Posted on: Tuesday,  May 1, 2012  8:25 AM ET by Wunderlich

Conceptus, Inc. (NASDAQ: CPTS)
rated Hold with price target $18 by Wunderlich.

Conceptus, Inc. develops, manufactures and markets the Essure permanent birth control system, a medical device for women that is approved for marketing in the United States by the United States Food and Drug Administration (FDA). The Essure system uses a soft and flexible micro-insert that is delivered into a woman's fallopian tubes to provide permanent birth control by causing benign tissue in-growth that blocks the fallopian tubes. A properly placed Essure micro-insert and the subsequent tissue growth prohibits the egg from traveling through the fallopian tubes and therefore prevents fertilization. On January 7, 2008, the Company acquired all of the outstanding shares of Conceptus SAS. Through Conceptus SAS, it sells Essure directly in France and uses distributors to sell Essure throughout the rest of Europe.

Advising private clients is a long-term and relationship-guided process. The Financial Advisors at Wunderlich Securities recognize that serving individuals and families requires an understanding of their individual goals and needs. Our approach involves a cycle of service. Wunderlich's Financial Advisors work with each client to design, implement and monitor a plan that serves the client's needs. We utilize a variety of high-quality investments including stocks, bonds, mutual funds, options and annuities to build diversified and balanced portfolios.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/1/2012 8:25 AM Hold
None
18.50 18.00
as of 12/31/2012
1 Week   
1 Month   
3 Months   
1 YTD   
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/10/2011 8:25 AM Hold
None
12.19 14.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy